Ospemifene
SIGMA/SML0996 - ≥98% (HPLC)
Synonym: (deaminohydroxy)
CAS Number: 128607-22-7
Empirical Formula (Hill Notation): C24H23ClO2
Molecular Weight: 378.89
Linear Formula: C24H23ClO2
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white to beige |
| form | powder |
| InChI | 1S/C24H23ClO2/c25-16-15-2 |
| InChI key | LUMKNAVTFCDUIE-VHXPQNKSSA |
| Quality Level | 100 ![]() |
| SMILES string | ClCCC(=C(c3ccc(cc3)OCCO |
| solubility | DMSO: 20 mg/mL, clear |
| storage temp. | 2-8°C |
| Biochem/physiol Actions: | Ospemifene is a selective estrogen receptor modulator (SERM), a metabolite of toremifene, with a unique estrogen agonist/antagonist tissue profile. Ospemifene was recently approved in the US for the treatment of dyspareunia associated with vulvar and vaginal atrophy in postmenopausal women, and is being investigated for the treatment and prevention of osteoporosis and breast cancer. Ospemifene binds ERα and ERβ with approximately equal affinities with IC50 values for estrogen receptor (ER) α and β of 0.8 μM and 1.7 μM, respectively. Ospemifene has estrogen-like effects on the vaginal epithelium and bone, antiproliferative effects in breast, and a neutral endometrial profile. |
| Biochem/physiol Actions: | Ospemifene is a selective estrogen receptor modulator (SERM), a metabolite of toremifene. |
| Packaging: | 10, 50 mg in glass bottle |
| Symbol | GHS09 |
| Signal word | Warning |
| Hazard statements | H410 |
| Precautionary statements | P273 - P501 |
| Hazard Codes | N |
| Risk Statements | 50/53 |
| Safety Statements | 60-61 |
| RIDADR | UN 3077 9 / PGIII |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 51111800 |


